Overview

PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural Mesothelioma

Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
Trial comparing standard treatment (chemotherapy) with pembrolizumab treatment in patients with advanced pretreated malignant mesothelioma.
Phase:
Phase 3
Details
Lead Sponsor:
European Thoracic Oncology Platform
Collaborators:
Frontier Science Foundation, Hellas
Merck Sharp & Dohme Corp.
Treatments:
Gemcitabine
Pembrolizumab
Vinblastine
Vinorelbine